Standardization of Polyherbal Formulations

Abstract

Polyherbal formulations sit at the heart of Ayurvedic therapeutics and at the centre of almost every outstanding reproducibility argument in clinical Ayurvedic research. A well-designed clinical trial of a polyherbal formulation is only as reliable as the formulation's compositional consistency from batch to batch. Standardisation is the technical bridge between classical polyherbal preparations and the modern pharmaceutical quality framework that European regulators, clinicians, and pharmacovigilance systems are built around. We reviewed 64 primary standardisation studies published between 2005 and 2021 covering the principal classical Ayurvedic polyherbal formulations (Triphala, Yograj Guggulu, Simhanad Guggulu, Nishamalaki, Dashamoola Kwatha, Chyawanprash, Maharasnadi Kwatha and close analogues), grouped under five standardisation frames: pharmacognostic identity (S1), chemical profiling by fingerprinting and marker quantification (S2), contaminant and safety screening (S3), bioactivity-guided standardisation (S4), and integrated multi-attribute standardisation (S5). Each frame was scored with the Polyherbal Standardisation Index (PHSI), a weighted composite across identity reliability, chemical fingerprint reproducibility, safety/contaminant control, batch-to-batch consistency and regulatory alignment. Integrated multi-attribute standardisation (S5) produced the highest PHSI (0.912). Chemical profiling (S2) was the strongest single frame at 0.864, but fell short of integrated systems on regulatory-alignment and batch-consistency dimensions. The study finds a consistent empirical signal: single-attribute standardisation is no longer sufficient for polyherbal formulations entering European clinical practice, and integrated systems are the minimum credible standard.